The average one-year price target for Cytokinetics (BIT:1CYTK) has been revised to €89.70 / share. This is an increase of 12.66% from the prior estimate of €79.62 dated April 27, 2026.
The price target is an average of many targets provided by analysts. The latest targets range from a low of €59.12 to a high of €130.04 / share. The average price target represents an increase of 40.68% from the latest reported closing price of €63.76 / share.
What is the Fund Sentiment?
There are 456 funds or institutions reporting positions in Cytokinetics. This is an decrease of 298 owner(s) or 39.52% in the last quarter. Average portfolio weight of all funds dedicated to 1CYTK is 0.32%, an increase of 36.93%. Total shares owned by institutions decreased in the last three months by 15.60% to 138,518K shares.
What are Other Shareholders Doing?
T. Rowe Price Investment Management holds 9,390K shares representing 7.55% ownership of the company. In its prior filing, the firm reported owning 19,080K shares , representing a decrease of 103.19%. The firm decreased its portfolio allocation in 1CYTK by 1.40% over the last quarter.
Vanguard Portfolio Management holds 5,844K shares representing 4.70% ownership of the company.
Vanguard Capital Management holds 5,489K shares representing 4.41% ownership of the company.
Deep Track Capital holds 3,337K shares representing 2.68% ownership of the company. In its prior filing, the firm reported owning 4,300K shares , representing a decrease of 28.86%. The firm decreased its portfolio allocation in 1CYTK by 42.68% over the last quarter.
Geode Capital Management holds 3,056K shares representing 2.46% ownership of the company. In its prior filing, the firm reported owning 3,040K shares , representing an increase of 0.52%. The firm increased its portfolio allocation in 1CYTK by 12.43% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
